Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...

The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...

The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that ...

RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...

Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on ...

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...

Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight ...

The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely ...

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...